Ensure you understand why both medications are necessary, what outcomes are expected, and whether alternative treatment approaches might be suitable
A 2022 systematic review and meta-analysis published in JAMA Internal Medicine found that GLP-1 receptor agonists were associated with increased risks of biliary disease compared to other diabetes medications, with higher risk observed at weight-loss doses and with longer duration of treatment
Diarrhea Occurs in approximately 15-25% of patients
2026 FDA Status GLP-1 patches are not FDA-approved for weight loss or any medical condition
Last reviewed: May 18, 2026 Last updated: May 18, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations